Skip to main content
. 2011 Apr 22;286(25):21982–21992. doi: 10.1074/jbc.M111.226795

FIGURE 9.

FIGURE 9.

A, panel I, the site of implantation of the clonal hybrid pancreatic beta cell line 1.1B4 in the subscapular region of the adult SCID mouse (asterisk). Panels ii and iii, the formation of the well vascularized subdermal 1.1B4-derived cell mass in a clear capsule (arrow). Panel iv, the average size of the cell mass on excision (day 28 after injection) was ∼21 × 14 mm. B, blood glucose measurements for SCID mice implanted with the 1.1B4 cell line at day 0 (arrow). Mice injected with 180 mg/kg of streptozotocin (stz) exhibited hyperglycemia between day −2 and day 0. Mice were monitored until day 28. C, glucose tolerance test showing blood glucose measurements between 0 and 90 min after intraperitoneal injection with 18 mmol/kg glucose (0 min) in both control (c1 and c2) and 1.1B4-implanted (i1 and i2), diabetic SCID mice. D, data for body weight, blood glucose, and plasma insulin at the termination of the in vivo experiment in individual SCID mice (day 28).